MXRA5

Summary

MXRA5 (matrix remodeling associated 5, HGNC:7539) is a protein-coding gene on chromosome Xp22.33, encoding Matrix-remodeling-associated protein 5 (Q9NR99). In kidney, has anti-inflammatory and anti-fibrotic properties by limiting the induction of chemokines, fibronectin and collagen expression in response to TGB1 and pro-inflammatory stimuli.

This gene encodes one of the matrix-remodelling associated proteins. This protein contains 7 leucine-rich repeats and 12 immunoglobulin-like C2-type domains related to perlecan. This gene has a pseudogene on chromosome Y.

Source: NCBI Gene 25878 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 630 total — 2 pathogenic, 1 likely-pathogenic
• MANE Select transcript: NM_015419

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7539
Approved symbol	MXRA5
Name	matrix remodeling associated 5
Location	Xp22.33
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp564I1922
Ensembl gene	ENSG00000101825
Ensembl biotype	protein_coding
OMIM	300938
Entrez	25878

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000217939

RefSeq mRNA: 1 — MANE Select: NM_015419 NM_015419

CCDS: CCDS14124

Canonical transcript exons

ENST00000217939 — 7 exons

Exon	Start	End
ENSE00000664560	3320008	3324975
ENSE00000664561	3330018	3330408
ENSE00000664562	3330644	3330773
ENSE00000870968	3317103	3318003
ENSE00001487548	3308565	3311624
ENSE00001487554	3343646	3343861
ENSE00001487556	3346515	3346652

Expression profiles

Bgee: expression breadth ubiquitous, 238 present calls, max score 99.79.

FANTOM5 (CAGE): breadth broad, TPM avg 9.7523 / max 537.9861, expressed in 687 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
198320	5.8448	535
198323	1.9988	489
198324	0.6689	320
198325	0.4605	272
198316	0.2634	134
198313	0.1195	53
198321	0.1183	58
198315	0.0874	40
198322	0.0670	26
198314	0.0582	20

Top tissues by expression

278 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tendon of biceps brachii	UBERON:0008188	99.79	gold quality
hair follicle	UBERON:0002073	99.05	gold quality
skin of hip	UBERON:0001554	98.90	gold quality
urethra	UBERON:0000057	98.84	gold quality
mammalian vulva	UBERON:0000997	98.73	gold quality
pylorus	UBERON:0001166	98.67	gold quality
cardia of stomach	UBERON:0001162	98.21	gold quality
parietal pleura	UBERON:0002400	98.12	gold quality
nipple	UBERON:0002030	97.98	gold quality
cervix squamous epithelium	UBERON:0006922	97.95	gold quality
penis	UBERON:0000989	97.94	gold quality
synovial joint	UBERON:0002217	97.93	gold quality
tibia	UBERON:0000979	97.79	gold quality
periodontal ligament	UBERON:0008266	97.76	gold quality
upper leg skin	UBERON:0004262	97.54	gold quality
mucosa of urinary bladder	UBERON:0001259	97.44	gold quality
pleura	UBERON:0000977	97.41	gold quality
mammary duct	UBERON:0001765	97.14	gold quality
visceral pleura	UBERON:0002401	97.08	gold quality
epithelium of mammary gland	UBERON:0003244	96.92	gold quality
mucosa of paranasal sinus	UBERON:0005030	96.89	gold quality
saphenous vein	UBERON:0007318	96.32	gold quality
vena cava	UBERON:0004087	96.01	gold quality
germinal epithelium of ovary	UBERON:0001304	95.46	gold quality
upper arm skin	UBERON:0004263	94.88	gold quality
pericardium	UBERON:0002407	94.73	gold quality
layer of synovial tissue	UBERON:0007616	94.73	gold quality
trachea	UBERON:0003126	94.39	gold quality
stromal cell of endometrium	CL:0002255	94.20	gold quality
renal medulla	UBERON:0000362	94.20	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-MTAB-8410	yes	34.58
E-HCAD-10	yes	29.88
E-MTAB-5061	yes	18.28
E-ANND-3	yes	6.61

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

98 targeting MXRA5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-450B-5P	99.92	71.48	3175

Literature-anchored findings (GeneRIF, showing 9)

• screened one most frequently mutated novel gene, matrix-remodeling associated 5 (MXRA5), in an additional larger Chinese sample set of 52 patients with NSCLC and confirmed its high somatic mutation frequency (PMID:22696596)
• These results indicated the potential value of MXRA5 as a novel therapeutic target for the treatment of non-small cell lung cancer. (PMID:26406953)
• In clear cell renal cancer, von Hippel-Lindau (VHL) regulated MXRA5 expression. (PMID:27599751)
• MXRA5 is downregulated in preeclamptic cytotrophoblasts and can regulate trophoblast cell invasion via the MAPK pathway. (PMID:28919298)
• Identification and functional activity of matrix-remodeling associated 5 (MXRA5) in benign hyperplastic prostate. (PMID:32392178)
• MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma. (PMID:34211612)
• Public RNA-seq data-based identification and functional analyses reveal that MXRA5 retains proliferative and migratory abilities of dental pulp stem cells. (PMID:37730838)
• Identification of HTRA1, DPT and MXRA5 as potential biomarkers associated with osteoarthritis progression and immune infiltration. (PMID:39148085)
• HIF-1alpha Activates Hypoxia-Induced MXRA5 Expression in the Progression of Ovarian Cancer. (PMID:39462449)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
danio_rerio	si:ch211-159i8.4	ENSDARG00000076332

Paralogs (36): CNTN1 (ENSG00000018236), CDON (ENSG00000064309), NEO1 (ENSG00000067141), SDK2 (ENSG00000069188), IGSF9B (ENSG00000080854), IGSF9 (ENSG00000085552), NRCAM (ENSG00000091129), IGDCC4 (ENSG00000103742), CNTN3 (ENSG00000113805), IGSF21 (ENSG00000117154), CNTN6 (ENSG00000134115), CHL1 (ENSG00000134121), PTPRQ (ENSG00000139304), CNTN4 (ENSG00000144619), BOC (ENSG00000144857), SDK1 (ENSG00000146555), HMCN2 (ENSG00000148357), NCAM1 (ENSG00000149294), CNTN5 (ENSG00000149972), IGSF10 (ENSG00000152580), ROBO4 (ENSG00000154133), ROBO3 (ENSG00000154134), NCAM2 (ENSG00000154654), VCAM1 (ENSG00000162692), NFASC (ENSG00000163531), PRTG (ENSG00000166450), ROBO1 (ENSG00000169855), DSCAM (ENSG00000171587), IGDCC3 (ENSG00000174498), VSIG10 (ENSG00000176834), DSCAML1 (ENSG00000177103), CNTN2 (ENSG00000184144), ROBO2 (ENSG00000185008), VSIG10L (ENSG00000186806), DCC (ENSG00000187323), L1CAM (ENSG00000198910)

Protein

Protein identifiers

Matrix-remodeling-associated protein 5 — Q9NR99 (reviewed: Q9NR99)

Alternative names: Adhesion protein with leucine-rich repeats and immunoglobulin domains related to perlecan

All UniProt accessions (1): Q9NR99

UniProt curated annotations — full annotation on UniProt →

Function. In kidney, has anti-inflammatory and anti-fibrotic properties by limiting the induction of chemokines, fibronectin and collagen expression in response to TGB1 and pro-inflammatory stimuli.

Subcellular location. Secreted.

Tissue specificity. Detected in placenta (at protein level). Detected in cerebrospinal fluid and fibroblasts (at protein level). Highly expressed in kidney, also detected on liver and spleen. Expressed by proximal tubular cells of the kidney (at protein level). Expression highly increases during chronic kidney disease and autosomal dominant polycystic kidney disease, where is detected in cysts.

Disease relevance. Lung cancer (LNCR) [MIM:211980] A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. Disease susceptibility may be associated with variants affecting the gene represented in this entry.

Induction. Expression is induced by TGFB1, in kidney tubular cells. This induction is inhibited by the vitamin D receptor activator paricalcitol (at protein level).

RefSeq proteins (1): NP_056234* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000372	LRRNT	Domain
IPR000483	Cys-rich_flank_reg_C	Domain
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013098	Ig_I-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR050467	LRFN	Family

Pfam: PF07679, PF13855, PF13927

UniProt features (89 total): sequence variant 22, domain 14, disulfide bond 12, region of interest 10, glycosylation site 9, compositionally biased region 8, repeat 7, sequence conflict 5, signal peptide 1, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

No AlphaFold model available for Q9NR99 — AlphaFold DB does not currently provide models for proteins above ~3000 aa.

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (12): 501–555, 599–651, 1875–1928, 1972–2025, 2069–2122, 2168–2221, 2265–2324, 2368–2418, 2466–2518, 2564–2616, 2659–2711, 2755–2810

Glycosylation sites (9): 287, 321, 633, 702, 1403, 1735, 2007, 2056, 2693

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 113 (showing top): GSE45365_NK_CELL_VS_CD8_TCELL_DN, TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL_UP, PEREZ_TP63_TARGETS, LINDGREN_BLADDER_CANCER_CLUSTER_3_DN, CHANDRAN_METASTASIS_DN, HANN_RESISTANCE_TO_BCL2_INHIBITOR_UP, PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP, LU_TUMOR_VASCULATURE_UP, GOBP_RESPONSE_TO_TRANSFORMING_GROWTH_FACTOR_BETA, GOMF_EXTRACELLULAR_MATRIX_STRUCTURAL_CONSTITUENT, ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN, TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_LOBULAR_NORMAL_DN, BROWNE_HCMV_INFECTION_24HR_DN, GOBP_RESPONSE_TO_GROWTH_FACTOR, PEREZ_TP53_AND_TP63_TARGETS

GO Biological Process (1): response to transforming growth factor beta (GO:0071559)

GO Molecular Function (2): extracellular matrix structural constituent (GO:0005201), protein binding (GO:0005515)

GO Cellular Component (3): extracellular matrix (GO:0031012), extracellular exosome (GO:0070062), extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
response to growth factor	1
structural molecule activity	1
extracellular matrix	1
binding	1
external encapsulating structure	1
extracellular vesicle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1246 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MXRA5	TBX2	Q13207	557
MXRA5	ARSF	P54793	500
MXRA5	ITGBL1	O95965	459
MXRA5	ANGPT2	O15123	447
MXRA5	GYG2	O15488	426
MXRA5	ARSD	P51689	410
MXRA5	JAG1	P78504	407
MXRA5	PRKX	P51817	400
MXRA5	FNDC1	Q4ZHG4	393
MXRA5	PUDP	Q08623	386
MXRA5	PNPLA4	P41247	382
MXRA5	ARSL	P51690	382
MXRA5	COL15A1	P39059	378
MXRA5	OLFML2B	Q68BL8	375
MXRA5	COL5A2	P05997	371

IntAct

19 interactions, top by confidence:

A	B	Type	Score
MXRA5	HMGN2	psi-mi:“MI:0915”(physical association)	0.400
MXRA5	PLEC	psi-mi:“MI:0915”(physical association)	0.400
MXRA5	CALR	psi-mi:“MI:0915”(physical association)	0.400
MXRA5	SDHA	psi-mi:“MI:0915”(physical association)	0.400
MFAP3L	MXRA5	psi-mi:“MI:0915”(physical association)	0.400
MPIG6B	MXRA5	psi-mi:“MI:0915”(physical association)	0.400
ILDR1	MXRA5	psi-mi:“MI:0915”(physical association)	0.400
MAG	MXRA5	psi-mi:“MI:0915”(physical association)	0.400
PILRA	MXRA5	psi-mi:“MI:0915”(physical association)	0.400
MXRA5	PILRB	psi-mi:“MI:0915”(physical association)	0.400
MXRA5	AGER	psi-mi:“MI:0915”(physical association)	0.400
MXRA5	SIGLEC7	psi-mi:“MI:0915”(physical association)	0.400
MXRA5	SIGLEC8	psi-mi:“MI:0915”(physical association)	0.400
MXRA5	SIGLEC1	psi-mi:“MI:0915”(physical association)	0.400
CD200	MXRA5	psi-mi:“MI:0915”(physical association)	0.400
SCN2B	MXRA5	psi-mi:“MI:0915”(physical association)	0.400
AXL	MXRA5	psi-mi:“MI:0915”(physical association)	0.400
EIF1B	MXRA5	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (9): MXRA5 (Affinity Capture-MS), MXRA5 (Affinity Capture-MS), MXRA5 (Affinity Capture-RNA), MXRA5 (Proximity Label-MS), MXRA5 (Proximity Label-MS), MXRA5 (Proximity Label-MS), MXRA5 (Proximity Label-MS), MXRA5 (Affinity Capture-MS), MXRA5 (Proximity Label-MS)

ESM2 similar proteins: A0A2R8Y4Y8, A0A2R8YFL7, A0A2R8YFM6, A0A8J1K1A4, A5D791, E7FKV8, O77726, O88393, P20239, P20783, P26342, P35054, P40200, P47984, Q03167, Q05996, Q08DT3, Q17R60, Q2Q0J1, Q3MHP9, Q3U0X8, Q3V1M1, Q4FZG8, Q4V7E2, Q5BK49, Q5SY80, Q5XI99, Q6DFV8, Q6WRH9, Q6WRI0, Q6X784, Q7TST5, Q80VH0, Q86WS3, Q8JIR8, Q8R1W8, Q925U0, Q95KG7, Q9D9J7, Q9ET62

Diamond homologs: A0N0X6, A2AJ76, A2CG49, A4IGL7, A4IIW9, B3NS99, B4GBH0, B4HNW4, B4KPU0, B4MR28, B4P5Q9, B4QC63, G5EBF1, O75325, O95428, P0C6S8, P11627, P12960, P22063, P28685, P32004, P97924, Q02246, Q07409, Q09024, Q12860, Q290N5, Q32Q07, Q3UQ28, Q3URE9, Q3V1M1, Q5R482, Q61330, Q61809, Q62682, Q62845, Q63198, Q66HV9, Q69Z26, Q6AWJ9

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 18 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	6	37.4×	5e-07

Disease & clinical

Clinical variants and AI predictions

ClinVar

630 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	1
Uncertain significance	354
Likely benign	34
Benign	27

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
2499158	GRCh37/hg19 Xp22.33-22.31(chrX:200855-6069814)x1	Pathogenic
564691	GRCh37/hg19 Xp22.33-22.31(chrX:168546-7796566)x1	Pathogenic
979822	GRCh37/hg19 Xp22.33-22.31(chrX:3185613-6333434)x1	Likely pathogenic

SpliceAI

714 predictions. Top by Δscore:

Variant	Effect	Δscore
X:3311625:C:CC	acceptor_gain	1.0000
X:3317097:GCCTA:G	donor_loss	1.0000
X:3317098:CCTA:C	donor_loss	1.0000
X:3317099:CTA:C	donor_loss	1.0000
X:3317100:TACC:T	donor_loss	1.0000
X:3317101:A:AT	donor_loss	1.0000
X:3317102:CCT:C	donor_loss	1.0000
X:3318001:CTC:C	acceptor_gain	1.0000
X:3330409:CTGC:C	acceptor_loss	1.0000
X:3343661:T:A	donor_gain	1.0000
X:3311620:CAAAA:C	acceptor_gain	0.9900
X:3311621:AAAA:A	acceptor_gain	0.9900
X:3311622:AAA:A	acceptor_gain	0.9900
X:3311623:AA:A	acceptor_gain	0.9900
X:3311624:AC:A	acceptor_loss	0.9900
X:3311624:ACTAC:A	acceptor_gain	0.9900
X:3311626:T:A	acceptor_gain	0.9900
X:3311626:T:C	acceptor_loss	0.9900
X:3318002:TC:T	acceptor_gain	0.9900
X:3318002:TCC:T	acceptor_loss	0.9900
X:3318003:CC:C	acceptor_gain	0.9900
X:3318004:C:CC	acceptor_gain	0.9900
X:3318004:CTGG:C	acceptor_loss	0.9900
X:3330251:T:TA	donor_gain	0.9900
X:3330407:AC:A	acceptor_gain	0.9900
X:3330408:CC:C	acceptor_gain	0.9900
X:3330409:C:CC	acceptor_gain	0.9900
X:3330419:A:T	acceptor_gain	0.9900
X:3330638:GTTTA:G	donor_loss	0.9900
X:3330639:TTTA:T	donor_loss	0.9900

AlphaMissense

18518 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:3323336:C:A	W783C	1.000
X:3323336:C:G	W783C	1.000
X:3309904:A:G	W2767R	0.999
X:3309904:A:T	W2767R	0.999
X:3310363:A:C	Y2614D	0.999
X:3310477:A:G	W2576R	0.999
X:3310477:A:T	W2576R	0.999
X:3311065:A:G	W2380R	0.999
X:3311065:A:T	W2380R	0.999
X:3311374:A:G	W2277R	0.999
X:3311374:A:T	W2277R	0.999
X:3317143:A:G	W2180R	0.999
X:3317143:A:T	W2180R	0.999
X:3317438:C:A	W2081C	0.999
X:3317438:C:G	W2081C	0.999
X:3317440:A:G	W2081R	0.999
X:3317440:A:T	W2081R	0.999
X:3317608:A:G	C2025R	0.999
X:3317731:A:G	W1984R	0.999
X:3317731:A:T	W1984R	0.999
X:3320026:A:G	W1887R	0.999
X:3320026:A:T	W1887R	0.999
X:3323338:A:G	W783R	0.999
X:3323338:A:T	W783R	0.999
X:3324551:C:A	W378C	0.999
X:3324551:C:G	W378C	0.999
X:3324553:A:G	W378R	0.999
X:3324553:A:T	W378R	0.999
X:3330767:A:C	N65K	0.999
X:3330767:A:T	N65K	0.999

dbSNP variants (sampled 300 via entrez): RS1000218906 (X:3344713 G>A), RS1000230950 (X:3313805 G>A), RS1000283254 (X:3314332 C>G,T), RS1000419890 (X:3326487 G>A,C), RS1000601177 (X:3336706 C>G), RS1000875308 (X:3326924 C>A,T), RS1000948023 (X:3346921 C>G), RS1001642747 (X:3328165 G>A,C,T), RS1002047621 (X:3347473 G>C), RS1002197881 (X:3314955 T>C), RS1002272772 (X:3337455 G>T), RS1002808962 (X:3318706 T>C), RS1002876728 (X:3329698 A>G), RS1002879541 (X:3339552 C>G), RS1002938906 (X:3329924 GAAT>G)

Disease associations

OMIM: gene MIM:300938 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): nephrotic syndrome (MONDO:0005377), prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST001613_13	Antineutrophil cytoplasmic antibody-associated vasculitis	1.000000e-06
GCST008162_27	Hip circumference	4.000000e-06

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D009404	Nephrotic Syndrome	C12.050.351.968.419.630.643; C12.200.777.419.630.643; C12.950.419.630.643
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

54 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, affects cotreatment, increases expression	5
bisphenol A	affects expression, affects cotreatment, increases expression	2
sodium arsenite	decreases expression, increases expression	2
Benzo(a)pyrene	affects methylation, decreases methylation, increases mutagenesis	2
Doxorubicin	decreases expression, increases expression	2
Ethinyl Estradiol	affects expression	2
Phenylmercuric Acetate	increases expression, affects cotreatment	2
Progesterone	affects cotreatment, decreases expression	2
Tobacco Smoke Pollution	decreases expression	2
bisphenol F	affects cotreatment, increases expression	1
testosterone enanthate	affects expression	1
sodium arsenate	decreases expression, increases abundance	1
2,5,2’,5’-tetrachlorobiphenyl	decreases expression	1
trichostatin A	increases expression	1
3,4-dichloroaniline	decreases expression	1
mono-(2-ethylhexyl)phthalate	decreases expression	1
zinc chromate	increases abundance, increases expression	1
chloroquine diphosphate	increases expression	1
aflatoxin B2	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	decreases expression	1
gallium arsenide	decreases expression	1
chromium hexavalent ion	increases abundance, increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
ICG 001	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Fulvestrant	decreases methylation	1
Troglitazone	decreases expression	1
Acetaminophen	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00308321	PHASE4	UNKNOWN	Long Term Tapering or Standard Steroids for Nephrotic Syndrome
NCT01021540	PHASE4	COMPLETED	Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes
NCT01028287	PHASE4	COMPLETED	Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)
NCT01162005	PHASE4	COMPLETED	Therapeutic Effect of Tacrolimus on Primary Nephrotic Syndrome in Children
NCT01895894	PHASE4	COMPLETED	Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome
NCT02238418	PHASE4	COMPLETED	Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria.
NCT02382575	PHASE4	UNKNOWN	Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Resistant Nephrotic Syndrome
NCT02427880	PHASE4	COMPLETED	Role of Acetazolamide and Hydrochlorothiazide Followed by Furosemide in Treating Nephrotic Edema
NCT03210688	PHASE4	COMPLETED	Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy
NCT03347357	PHASE4	COMPLETED	Pharmacokinetics of Tacrolimus in Children
NCT05696977	PHASE4	UNKNOWN	Effect of Obesity on Cyclosporine Blood Trough Level in Nephrotic Syndrome Patients
NCT05966818	PHASE4	UNKNOWN	Effect of Dapagliflozin in Non-Diabetic Patients With Nephrotic Syndrome.
NCT06026787	PHASE4	COMPLETED	Clinical Value of Adding Dapagliflozin in Patients With Nephrotic Syndrome
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device